- Home
- WNEB vs ME Comparison
WNEB vs ME Comparison
Compare WNEB & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- ME
- Stock Information
- Founded
- WNEB 1853
- ME 2006
- Country
- WNEB United States
- ME United States
- Employees
- WNEB N/A
- ME N/A
- Industry
- WNEB Savings Institutions
- ME Precision Instruments
- Sector
- WNEB Finance
- ME Health Care
- Exchange
- WNEB Nasdaq
- ME Nasdaq
- Market Cap
- WNEB 165.5M
- ME 168.9M
- IPO Year
- WNEB N/A
- ME N/A
- Fundamental
- Price
- WNEB $8.67
- ME $0.32
- Analyst Decision
- WNEB Hold
- ME Hold
- Analyst Count
- WNEB 4
- ME 1
- Target Price
- WNEB $8.50
- ME $0.47
- AVG Volume (30 Days)
- WNEB 39.9K
- ME 2.4M
- Earning Date
- WNEB 10-22-2024
- ME 11-06-2024
- Dividend Yield
- WNEB 3.28%
- ME N/A
- EPS Growth
- WNEB N/A
- ME N/A
- EPS
- WNEB 0.63
- ME N/A
- Revenue
- WNEB $74,435,000.00
- ME $199,188,000.00
- Revenue This Year
- WNEB N/A
- ME $0.05
- Revenue Next Year
- WNEB $5.16
- ME $17.98
- P/E Ratio
- WNEB $13.47
- ME N/A
- Revenue Growth
- WNEB N/A
- ME N/A
- 52 Week Low
- WNEB $6.00
- ME $0.29
- 52 Week High
- WNEB $9.25
- ME $1.13
- Technical
- Relative Strength Index (RSI)
- WNEB 60.39
- ME 44.05
- Support Level
- WNEB $8.51
- ME $0.29
- Resistance Level
- WNEB $8.99
- ME $0.32
- Average True Range (ATR)
- WNEB 0.18
- ME 0.02
- MACD
- WNEB -0.05
- ME 0.00
- Stochastic Oscillator
- WNEB 46.67
- ME 61.22
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.